Test Price
2,800 AED✅ Home Collection Available
JUP Gene Arrhythmogenic Right Ventricular Cardiomyopathy Type 12 Genetic Test in UAE | 2,800 AED | DHA Licensed Laboratory
Executive Summary & Core Metrics
Diagnostic Accuracy: 99.9% analytical sensitivity and specificity via ISO 9001:2015 certified Next Generation Sequencing (NGS) processing for full JUP gene coverage including copy number variant analysis.
Specimen Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM across all seven emirates.
Clinical Oversight: Post-test telephonic result interpretation and genetic counseling provided by Consultant Medical Genetics specialist Lina Osama Zaki Quteineh (DHA Registration ID: 9294403).
Insurance & Billing: Direct billing verification available via WhatsApp +971 54 548 8731.
Regulatory Compliance: This test adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL), Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, and Federal Decree-Law No. 4 of 2016 on Medical Liability for patient safety and informed consent.
Test Overview & Methodology
The JUP gene NGS test detects germline pathogenic variants associated with arrhythmogenic right ventricular cardiomyopathy type 12 (ARVC-12), a hereditary cardiac condition that predisposes individuals to ventricular arrhythmias and sudden cardiac death. This analysis enables pre-symptomatic risk stratification, cascade family screening, and informed clinical management for at-risk individuals. The assay employs Illumina-based next generation sequencing with full exon coverage, flanking intronic regions, and concurrent copy number variant detection to ensure comprehensive molecular characterization.
| Feature | Our Test | Closest Alternative |
|---|---|---|
| Analytical Scope | NGS with full gene coverage, intronic boundaries, and CNV analysis | Sanger sequencing limited to known hotspot exons |
| Platform | Next Generation Sequencing (Illumina platform) | PCR-based targeted mutation panel |
| Turnaround Time | 3–4 Weeks | 4–6 Weeks |
Physician Insight & Safety Protocols
"Genetic testing for the JUP gene provides essential risk stratification for arrhythmogenic right ventricular cardiomyopathy type 12. However, a detected variant must always be interpreted alongside clinical phenotype, family pedigree, and electrocardiographic findings. A positive result indicates elevated lifetime risk but does not confirm active disease in the absence of diagnostic criteria. Conversely, a negative result does not exclude other genetic or acquired cardiomyopathies. Multidisciplinary evaluation including cardiology and genetics consultation remains the standard of care."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA: 9294403)
⚠️ Important Advisory
This genetic test is a supplementary diagnostic tool and does not replace ongoing cardiology care. Do not discontinue, alter, or initiate any prescribed medication or therapeutic regimen based solely on genetic results without direct consultation with your treating physician.
Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Testing is not recommended for asymptomatic minors without explicit legal guardian consent obtained through documented genetic counseling. This assay is contraindicated during acute myocardial infarction, hemodynamic instability, or decompensated heart failure where immediate clinical intervention takes precedence.
- Emergency Red Flags: Seek immediate emergency care if you experience new-onset syncope (fainting), sustained palpitations, chest pain, or sudden shortness of breath. A pending genetic result must never delay evaluation or management of acute arrhythmias or heart failure symptoms.
Patient FAQ & Clinical Guidance
1. What is the purpose of the JUP gene genetic test?
This test identifies inherited pathogenic variants in the JUP gene that increase lifetime risk of arrhythmogenic right ventricular cardiomyopathy type 12 (ARVC-12). It is used for pre-symptomatic risk assessment, family cascade screening, and guiding clinical surveillance strategies in at-risk individuals.
2. Who should consider undergoing this genetic test?
Individuals with a personal or family history of ARVC, unexplained syncope, ventricular arrhythmias, or sudden cardiac death, particularly in relatives under age 40. First-degree relatives of a known JUP variant carrier are also strongly advised to consider testing after genetic counseling.
3. How is the sample collected for this test?
Sample collection requires a standard peripheral whole blood draw (EDTA tube) or saliva specimen. Our VIP mobile phlebotomy service performs home collection across the UAE between 8 AM and 11 PM, with temperature-controlled cold-chain transport to the ISO 9001:2015 certified laboratory.
4. What does a positive result mean for my family members?
A positive result indicates that a specific genetic variant is present, meaning each first-degree relative (parents, siblings, children) has a 50% chance of carrying the same variant. Cascade testing and cardiology evaluation for at-risk relatives is strongly recommended, accompanied by expert genetic counseling.
5. Is genetic counseling provided with this test?
Yes, all patients receive pre-test and post-test telephonic genetic counseling with a board-certified Consultant Medical Genetics specialist. This ensures informed consent, accurate result interpretation, and personalized risk management planning in accordance with UAE regulatory standards.
UAE Regulatory & Data Privacy Adherence
Data Protection & Health Information Governance: All genetic data is processed and stored in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient genomic information is anonymized, encrypted at rest and in transit, and access-restricted to authorized clinical personnel only. No genetic data is shared with third parties without explicit written consent. Clinical safety and informed consent procedures are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability.
Laboratory Accreditation: DNA Labs UAE operates under DHA Facility License Number 1143 and maintains ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139), ensuring rigorous quality management across all pre-analytical, analytical, and post-analytical processes.
Clinical & Logistical Metadata
| Test Name | JUP Gene Arrhythmogenic Right Ventricular Cardiomyopathy Type 12 Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA) or Saliva |
| Methodology Used | Next Generation Sequencing (NGS) – Illumina Platform with Full Gene Coverage & CNV Analysis |
| ICD-10-CM Code | I42.8 |
| LOINC Code | 82207-7 |
| DHA Facility License & Laboratory Address | DHA License #1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians